Overview
Ikena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. Ikena is advancing five development and discovery programs: an EP4 receptor antagonist; an AHR antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.